A phase III study – Semaglutide improves symptoms for heart failure patients with preserved ejection and obesity
Heart failure with preserved ejection fraction (HFpEF) is one of the leading causes of death, with increasing prevalence due to the pandemic of metabolic disorders. About 80% of HFpEF patients are obese, along with other metabolic diseases, and there is no effective treatment available.
